ARTICLE FROM BIO X CELL
A publication summary describing oncolytic virus driven combination immunotherapy in disease models
Bio X Cell has recently published a scientific blog article featuring a journal publication that highlights a research study conducted by team of investigators led by John Cameron Bell, describing a novel combination of T-cell based immunotherapy and oncolytic viruses in disease models.
Read more about the publication summary, have a glance at some featured in vivo antibodies for your next research project from Bio X Cell, as well as explore additional related Bio X Cell antibodies for cancer and immunology research.
All products listed on this site and sold through LAB-A-PORTER Limited are for research use only (RUO). Not for human use. Not for therapeutic or diagnostic use.
ABOUT BIO X CELL
Antibodies For In Vivo Research
Bio X Cell antibodies are formulated for in vivo experiments and used extensively in animal models of human disease. They feature greater than 95% purity, ultra-low endotoxin levels, and are presevative, stabilizer, and carrier protein-free. Bio X Cell has developed a wide range of antibodies for immuno-oncology, immunology, and neuroscience research. Their products are cited in over 15,000 publications that detail a broad range of applications, including in vivo cell-specific depletion, cytokine neutralization, immune checkpoint blockade, and more.
-
- Exceptional Purity
- Pathogen Free
- Ultra-low Endotoxin Level
- Advanced Binding Validation
- Low Protein Aggregation
- Marching Isotype Control Antibodies
All products listed on this site and sold through LAB-A-PORTER Limited are for research use only (RUO). Not for human use. Not for therapeutic or diagnostic use.
Reference:
- Bio X Cell, ‘Oncolytic virus driven combination immunotherapy shows promise in colorectal cancer’ Available at https://bioxcell.com/oncolytic-virus-driven-combination/